Clinical trials: Advanced Head and Neck Cancer
Solid Tumor, Triple-negative Breast Cancer
A Study of LY3435151 in Participants With Solid Tumors
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04099277
- Testing
- LY3435151, Pembrolizumab
- Where
- 2 sites in United States, Japan
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Therapeutic Patient Education, Immune Checkpoint Inhibitors
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI
- Conditions
- Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma, Advanced Non-small Cell Lung Cancer
- Trial name
- EDHITO (NCT03948724)
- Testing
- Therapeutic education program, Usual Information
- Where
- 9 sites in France
- Volunteers
- 412 people
- Sponsor
- Institut Cancerologie de l'Ouest
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00757172
- Testing
- panitumumab, cisplatin, docetaxel
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01307267
- Testing
- PF-05082566, rituximab
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 190 people
- Sponsor
- Pfizer
Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
This is a single-arm, non-randomized pilot study to evaluate the efficacy and tolerability of combination quad-shot palliative radiotherapy with immunotherapy for advanced/recurrent/metastatic head and neck cancer.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT04454489
- Testing
- Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer, Carcinoma, Squamous Cell
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
The purpose of this study is to determine if combination Erlotinib, Cisplatin/Carboplatin, and Paclitaxel are effective first line treatment for metastatic, recurrent and persistent squamous cell carcinoma of the head and neck.
- Trial name
- NCT00448240
- Testing
- Erlotinib
- Volunteers
- 6 people
- Sponsor
- Henry Ford Health System
Head and Neck Neoplasms
Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer
The aim for the present study named RAREST (RAdiotherapy RElated Skin Toxicity) is to compare the new dressing with the standard skin care.
- Trial name
- RAREST-01 (NCT03047174)
- Testing
- Mepitel® Film, Standard Care
- Where
- 2 sites in Germany
- Volunteers
- 57 people
- Sponsor
- University Hospital Schleswig-Holstein
Squamous Cell Carcinoma of the Head and Neck
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
There are currently no useful tests to identify patients who will respond to cetuximab therapy, notably because EGFR levels do not correlate with the clinical responses observed.
- Trial name
- NCT01218048
- Testing
- Cetuximab, Surgery, Post-surgical radiation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robert Ferris
Esophageal Squamous Cell Carcinoma
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
The study aimed to evaluate the efficacy and safety of sitravatinib in combination with tislelizumab as a second- or third-line treatment for participants with locally advanced, unresectable, or metastatic esophageal squamous…
- Trial name
- NCT05461794
- Testing
- Sitravatinib, Tislelizumab, Docetaxel
- Where
- 31 sites in China
- Volunteers
- 96 people
- Sponsor
- BeiGene
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer
- Trial name
- NCT00607594
- Testing
- saracatinib
- Where
- 5 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
This phase II trial studies how well inolitazone dihydrochloride (efatutazone dihydrochloride) and paclitaxel work in treating patients with anaplastic thyroid cancer that has spread to other places in the body and usually cannot…
- Trial name
- NCT02152137
- Testing
- efatutazone, paclitaxel
- Where
- 253 sites in United States
- Volunteers
- 19 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Salivary Gland Cancer, Recurrent Salivary Gland Cancer
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers.
- Conditions
- Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma
- Trial name
- NCT05010629
- Testing
- 9-ING-41, Carboplatin, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Robert Haddad, MD
Head and Neck Cancer
RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
The purpose of this study is to determine if RAD001, to a maximum dose of 10 mg/day, can be safely administered with cisplatin, and concurrent radiotherapy, for patients with locally advanced, inoperable, squamous cell carcinoma…
- Trial name
- NCT01057277
- Testing
- RAD001(Afinitor)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- howard safran
Head and Neck Squamous Cell Carcinoma
Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
Objective: Primary objective: To evaluate the major pathologic response (mPR) of locally advanced head and neck cancer after paclitaxel and carboplatin-induction chemotherapy followed by surgery.
- Trial name
- NEOS (NCT05294900)
- Testing
- paclitaxel/carboplatin
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Yonsei University
Advanced Cancer
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with…
- Trial name
- NCT03674567
- Testing
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Cancer
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
- Trial name
- NCT04106492
- Testing
- SQ3370
- Where
- 10 sites in United States, Australia
- Volunteers
- 53 people
- Sponsor
- Shasqi, Inc.
Head and Neck Neoplasms
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and…
- Trial name
- NCT03040999
- Testing
- Pembrolizumab, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy
- Where
- 151 sites in United States, Australia and 19 more
- Volunteers
- 804 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Head and Neck
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT05459129
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to…
- Conditions
- NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer
- Trial name
- NCT03207867
- Testing
- NIR178, PDR001
- Where
- 21 sites in United States, Argentina and 13 more
- Volunteers
- 315 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
This trial that is investigating a medication called duvelisib in combination with docetaxel for the treatment of squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread outside the head and neck area.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer
- Trial name
- NCT05057247
- Testing
- Duvelisib, Docetaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Kartik Sehgal, MD